Astley-Sparke Philip
SEC insider (Form 3/4/5 filer). CIK 0001376491. Director at Replimune Group, Inc. (REPL) and 1 other issuer. 7 reported Form 4/5 transactions since Sep 2024; latest on Aug 20, 2026. Located in WOBURN, MA.
Companies Astley-Sparke Philip has filed insider reports for
- Replimune Group, Inc. (REPL): Director
- enGene Therapeutics Inc. (ENGN): Director
Astley-Sparke Philip
CIK: 0001376491
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Aug 20, 2026REPL
Replimune Group, Inc.
GiftDirect50K shares- - Jun 16, 2026ENGN
enGene Therapeutics Inc.
AwardDirectStock Option (Right to Buy)
31K shares- - May 18, 2026REPL
Replimune Group, Inc.
SaleDirect17.7K shares at avg. $5.08$90K - Apr 1, 2026REPL
Replimune Group, Inc.
AwardDirect50K shares- - Feb 18, 2026REPL
Replimune Group, Inc.
GiftDirect25K shares- - Jul 8, 2025ENGN
enGene Holdings Inc.
AwardDirectStock Option (Right to Buy)
45K shares- - May 20, 2025REPL
Replimune Group, Inc.
SaleDirect32.3K shares at avg. $8.06$260K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 20, 2026 |  REPL Replimune Group, Inc. | Gift | 50,000 | - | $0 | Direct |
| Jun 16, 2026 |  ENGN enGene Therapeutics Inc. | Award Stock Option (Right to Buy) | 31,000 | - | - | Direct |
| May 18, 2026 | REPL Replimune Group, Inc. | Sale | 17,657 | $5.08 | $89,698 | Direct |
| Apr 1, 2026 | REPL Replimune Group, Inc. | Award | 50,000 | - | $0 | Direct |
| Feb 18, 2026 | REPL Replimune Group, Inc. | Gift | 25,000 | - | $0 | Direct |
| Jul 8, 2025 | ENGN enGene Holdings Inc. | Award Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| May 20, 2025 | REPL Replimune Group, Inc. | Sale | 32,279 | $8.06 | $260,169 | Direct |
1-7 of 7 transactions